Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma 8Recurrence 3Lymphoma, Follicular 3Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, B-Cell, Marginal Zone 2Leukemia 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Hodgkin Disease 1

Interventions

Cisplatin 12Irinotecan 10Specimen Handling 8Fluorouracil 8Oxaliplatin 7Magnetic Resonance Spectroscopy 6Trastuzumab 5Leucovorin 5Capecitabine 5Biopsy 5Neoadjuvant Therapy 4Docetaxel 4fludarabine 3Radiotherapy 3Paclitaxel 3Interleukin-12 Subunit p35 3Epirubicin 3Cyclophosphamide 3Chemotherapy, Adjuvant 3trastuzumab deruxtecan 2talazoparib 2bryostatin 1 2aldesleukin 2X-Rays 2Psychiatric Rehabilitation 2Platinum 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Microarray Analysis 2Magnetic Resonance Imaging 2MK 2206 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Stomach Neoplasms × Chlorambucil × Clear all
NCT00003617 2013-09-20

Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach

National Cancer Institute (NCI)

Phase 3 Unknown
200 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡